Von Willebrand Factor Antigen and Functions, Factor VIII activity and Fibrinogen Levels were Significantly Increased in Patients with Chronic Kidney Disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20160318001

Enrollment

252

Registered

2016-03-18

Start date

2015-09-14

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease without renal replacement therapy chronic kidney disease&#44

Interventions

Healthy volunteers without underlying diseases and estimated GFR >/= 90 ml/min/1.73 m2 . No medication.,Patients who have estimated GFR >/= 90 ml/min/1.73 m2 >/= 3 months with identification of kidney

urine findings&#44

and radiology.,Patients who have estimated GFR 60&#45

89 ml/min/1.73 m2 >/= 3 months with identification of kidney damage by structure or function.,Patients who have estimated GFR 30&#45

59 ml/min/1.73 m2 >/= 3 months.,Patients who have estimated GFR 15&#45

29 ml/min/1.73 m2 >/= 3 months.,Patients who have estimated GFR /= 3 months without renal replacement therapy

Basic Science,Basic Science,Basic Science,Basic Science,Basic Science,Basic Science

healthy volunteers,Chronic kidney disease staging 1,Chronic kidney disease staging 2,Chronic kidney disease staging 3,Chronic kidney disease staging 4,Chronic kidney disease staging 5

Eligibility

Sex/Gender

All

Age

18 Years to 0 Years

Inclusion criteria

Inclusion criteria: Disease group 1. age >/= 18 years 2. chronic kidney disease defined by structural or functional abnormality Healthy volunteers 1. age >/= 18 years 2. eGFR >/= 90 ml/min/1.73 m2 3. no underlying disease

Exclusion criteria

Exclusion criteria: 1. on medication affecting platelet function, and coagulation system. 2. Hematocrit < 25%, Platelet < 100,000/cu.mm. 3. Diseases: platelet dysfunction (chronic myeloid leukemia), von Willebrand disease 4. on renal replacement therapy

Design outcomes

Primary

Measure	Time frame
platelet function once bleeding time, platelet aggregation test, platelet activation by flow cytometry, vWF assays	—

Secondary

Measure	Time frame
corneal staining score,ocular symptom score before and after 2 intervention, 1 week apart fluorescein corneal staining for corneal staining score and questionnaire for ocular symptom score	—

Countries

Thailand

Contacts

Public ContactRatana Chawanasuntorapoj

Faculty of Medicine Siriraj Hospital

ratana99@gmail.com0846408889

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Von Willebrand Factor Antigen and Functions&#44; Factor VIII activity and Fibrinogen Levels were Significantly Increased in Patients with Chronic Kidney Disease